Omada Health (OMDA) – Analysts’ Recent Ratings Updates

Omada Health (NASDAQ: OMDA) recently received a number of ratings updates from brokerages and research firms:

• 5/8/2026 – Omada Health had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc..
• 5/8/2026 – Omada Health had its “outperform” rating reaffirmed by Evercore Inc. They now have a $20.00 price target on the stock.
• 5/8/2026 – Omada Health was given a new $24.00 price target by Canaccord Genuity Group Inc..
• 5/8/2026 – Omada Health had its “outperform” rating reaffirmed by Citigroup Inc..
• 5/8/2026 – Omada Health had its price target raised by Barclays PLC from $18.00 to $20.00. They now have an “overweight” rating on the stock.
• 5/8/2026 – Omada Health had its price target raised by Citizens Jmp from $18.00 to $21.00. They now have a “market outperform” rating on the stock.
• 5/8/2026 – Omada Health had its price target raised by Wells Fargo & Company from $17.00 to $18.00. They now have an “equal weight” rating on the stock.
• 5/8/2026 – Omada Health had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $28.00 price target on the stock.
• 4/14/2026 – Omada Health is now covered by Citigroup Inc.. They set an “outperform” rating on the stock.
• 4/14/2026 – Omada Health is now covered by Citizens Jmp. They set an “outperform” rating and a $18.00 price target on the stock.
• 4/9/2026 – Omada Health had its price target lowered by The Goldman Sachs Group, Inc. from $26.00 to $23.00. They now have a “buy” rating on the stock.
• 4/8/2026 – Omada Health had its “outperform” rating reaffirmed by Evercore Inc. They now have a $15.00 price target on the stock.

Insider Activity at Omada Health

In other Omada Health news, President Wei-Li Shao sold 2,829 shares of the firm’s stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $12.71, for a total value of $35,956.59. Following the completion of the transaction, the president owned 328,850 shares of the company’s stock, valued at approximately $4,179,683.50. This trade represents a 0.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sean P. Duffy sold 4,063 shares of the firm’s stock in a transaction on Monday, March 9th. The stock was sold at an average price of $14.34, for a total transaction of $58,263.42. Following the completion of the transaction, the chief executive officer directly owned 117,598 shares of the company’s stock, valued at approximately $1,686,355.32. This represents a 3.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 8,776 shares of company stock valued at $120,483 over the last 90 days. Insiders own 6.38% of the company’s stock.

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.